Supporting Information

Files in this Data Supplement:

Fig. 7. Bortezomib administration to bone marrow transplant recipients does not impair engraftment or myeloid reconstitution. Mice were analyzed at various time points after transplant for myeloid reconstitution and donor engraftment. (A) B6 mice received 15 million BALB/c BMC after lethal irradiation. Some mice also received 20 million spleen cells to induce GVHD. Administration of 15 mg per dose bortezomib on days 0 through +2 post-BMT had no significant effect on peripheral blood cell (WBC) or platelet (PLT) recovery on days 14 and 28 post-BMT compared with mice that received vehicle control. (B) Surviving mice were analyzed for donor cell engraftment on day 70 post-BMT. All mice that received spleen cells and vehicle control (PBS) treatment succumbed to GVHD before analysis. No significant differences in donor cell chimerism were observed in mice that received 10 mg per dose bortezomib on days 0 through +2 post-BMT with (▲) or without (¨) spleen cells and mice that received vehicle control (PBS) treatment (▼). GVHD, graft-versus-host disease; BMT, bone marrow transplantation; SC, splenocyte; PBL, peripheral blood leukocyte.